Trial · NCT03061812
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Topotecan | 8.57 | 95% Confidence Interval 7.69 to 10.12 | months | |
| Overall Survival (OS) | Rovalpituzumab Tesirine | 6.34 | 95% Confidence Interval 5.55 to 7.33 | months | |
| Progression Free Survival (PFS) | Topotecan | 4.27 | 95% Confidence Interval 3.75 to 5.42 | months | |
| Progression Free Survival (PFS) | Rovalpituzumab Tesirine | 3.02 | 95% Confidence Interval 2.86 to 3.61 | months | |
Change From Baseline of the Physical Functioning Scale Score in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care (EORTC QLQ-C15-PAL) at Week 7 | Topotecan | -7.16 | 95% Confidence Interval -11.95 to -2.36 | score on a scale | |
Change From Baseline of the Physical Functioning Scale Score in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care (EORTC QLQ-C15-PAL) at Week 7 | Rovalpituzumab Tesirine | -7.66 | 95% Confidence Interval -11.31 to -4.01 | score on a scale | |
| Objective Response Rate (ORR) | Topotecan | 20.9 | 95% Confidence Interval 14.27 to 28.97 | percentage of participants | |
| Objective Response Rate (ORR) | Rovalpituzumab Tesirine | 14.6 | 95% Confidence Interval 10.75 to 19.26 | percentage of participants | |
| Clinical Benefit Rate (CBR) | Topotecan | 43.4 | 95% Confidence Interval 34.71 to 52.42 | percentage of participants | |
| Clinical Benefit Rate (CBR) | Rovalpituzumab Tesirine | 35.9 | 95% Confidence Interval 30.34 to 41.74 | percentage of participants | |
| Duration of Objective Response (DOR) | Topotecan | 4.86 | 95% Confidence Interval 3.94 to 7.85 | months | |
| Duration of Objective Response (DOR) | Rovalpituzumab Tesirine | 3.52 | 95% Confidence Interval 2.76 to 4.17 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03061812/results